Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 13/20 | 0.66 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.60 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.53 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.53 |
| ▸ | TCF4 | P15884 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012238 | 0.83 | TAS2R14 (0.58) | TAS2R14CXCR3PTGESTAS2R8MEP1B | |
| SCHEMBL29691491 | 0.83 | TAS2R14 (0.58) | TAS2R14CXCR3PTGESTAS2R8MEP1B | |
| SCHEMBL1169358 | 0.83 | TAS2R14 (0.82) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL29757354 | 0.82 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL29691981 | 0.82 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL1278475 | 0.81 | TAS2R14 (0.67) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL23364591 | 0.81 | TAS2R14 (0.74) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL23364620 | 0.81 | TAS2R14 (0.74) | TAS2R14CXCR3PTGESTAS2R8MAPT | |
| SCHEMBL6122252 | 0.81 | TAS2R14 (0.74) | TAS2R14CXCR3PTGESTAS2R8MAPT | |
| SCHEMBL10119378 | 0.80 | TSHR (0.64) | ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | TAS2R14 1603/4885CXCR3 3092/4885PTGES 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.